血液腫瘤檢測市場、機會、成長動力、產業趨勢分析與預測，2024-2032

2023 年，全球血液腫瘤檢測市場估值為32 億美元，預計2024 年至2032 年複合年成長率為14.2%。率不斷上升推動的，導致對先進診斷測試的需求增加。診斷技術的進步，加上人們對血液癌症的認知提高以及早期檢測的好處，正在顯著推動市場發展。對早期篩檢的日益關注和更專業的檢測解決方案的開發繼續推動市場向前發展。

血液腫瘤學檢測致力於血液相關癌症的檢測、診斷和監測。這些測試可識別基因突變、染色體異常以及與血液惡性腫瘤相關的其他生物標記物，從而增強更有效地管理這些疾病的能力。

整個血液腫瘤檢測產業根據產品和服務、癌症類型、技術、最終用途和地區進行分類。

市場分為試劑盒和試劑、儀器以及軟體和服務。儀器部分包括次世代定序（NGS）、聚合酶鏈反應（PCR）、流式細胞儀、細胞遺傳學和免疫組織化學。 2023 年，在個人化醫療需求不斷成長和診斷測試進步的推動下，試劑盒和試劑領域佔據主導地位，收入達 17 億美元。血液學診斷的持續研究和開發進一步刺激了市場擴張，FDA 和 EMA 等機構的監管批准支持了成長。

市場分為白血病、淋巴瘤和其他癌症。由於霍奇金淋巴瘤和非何杰金氏淋巴瘤的發生率不斷上升，淋巴瘤在 2023 年佔據了 51.3% 的領先市場。改進的篩檢計劃和診斷技術有助於該細分市場的主導地位。

主要最終用戶包括醫院和診所、診斷實驗室和其他實體。在醫療保健基礎設施投資增加以及與研究機構合作的推動下，診斷實驗室預計從 2024 年到 2032 年將以 14.5% 的複合年成長率成長。這些進步正在提高測試能力並促進創新。

由於血液癌症發病率上升以及先進檢測技術的迅速採用，北美在 2023 年佔據全球市場最大佔有率，達到 45.6%。在醫療基礎設施的進步、有利的報銷政策以及監管機構對新型檢測方法的認可的支持下，美國市場從 2024 年到 2032 年的複合年成長率預計將達到 14.1%。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 提高血液癌症的診斷率
    • 改善醫療基礎設施
    • 診斷技術的進步
    • 血液系統惡性腫瘤的發生率增加
  • 產業陷阱與挑戰
    • 來自替代診斷方法的競爭
    • 維護和營運成本高
• 成長潛力分析
• 監管環境
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品和服務分類，2021 - 2032 年

• 主要趨勢
• 樂器
  • 新一代定序 (NGS)
  • 聚合酶鍊式反應 (PCR)
  • 流式細胞儀
  • 細胞遺傳學
  • 免疫組織化學 (IHC)
  • 其他技術
• 試劑盒和試劑
• 軟體與服務

第 6 章：市場估計與預測：按癌症類型，2021 - 2032 年

• 主要趨勢
• 白血病
  • 急性淋巴性白血病（ALL）
  • 急性骨髓性白血病（AML）
  • 慢性淋巴性白血病（CLL）
  • 慢性骨髓性白血病（CML）
• 淋巴瘤
  • 霍奇金淋巴瘤
  • 非何杰金氏淋巴瘤 (NHL)
• 其他癌症類型

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院和診所
• 診斷實驗室
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbott Laboratories
• ARUP Laboratories
• Bio-Rad Laboratories Inc.
• Danaher Corporation (Integrated DNA Technologies, Inc.)
• Entrogen Inc.
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Invivoscribe, Inc.
• Invitae Corporation (Archerdx, Inc.)
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Vela Diagnostics

The Global Hemato Oncology Testing Market was valued at USD 3.2 billion in 2023 and is projected to grow at a CAGR of 14.2% from 2024 to 2032. This growth is driven by the increasing prevalence of hematological cancers, including leukemia, lymphoma, and multiple myeloma, leading to a rise in demand for advanced diagnostic tests. The advancements in diagnostic technology, in line with greater awareness of hematologic cancers and the benefits of early detection, are significantly boosting the market. The growing focus on early screening and the development of more specialized testing solutions continue to propel the market forward.

Hemato oncology testing is dedicated to the detection, diagnosis, and monitoring of blood-related cancers. These tests identify genetic mutations, chromosomal abnormalities, and other biomarkers associated with hematologic malignancies, enhancing the ability to manage these diseases more effectively.

The overall hemato oncology testing industry is categorized based on Product and Service, Cancer Type, Technology, End-use, and Region.

The market is segmented into kits and reagents, instruments, and software and services. The instrument segment includes next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, cytogenetics, and immunohistochemistry. In 2023, the kits and reagents segment dominated with a revenue of USD 1.7 billion, driven by the increasing demand for personalized medicine and advancements in diagnostic testing. Continuous research and development in hematology diagnostics further stimulates market expansion, with regulatory approvals from bodies like the FDA and EMA supporting growth.

The market is categorized into leukemia, lymphoma, and other cancers. Lymphoma held a leading market share of 51.3% in 2023 due to the rising incidence of both Hodgkin's and non-Hodgkin's lymphoma. Improved screening programs and diagnostic techniques contribute to the segment's dominance.

Key end-users include hospitals and clinics, diagnostic laboratories, and other entities. Diagnostic laboratories are expected to grow at a CAGR of 14.5% from 2024 to 2032, driven by increased investments in healthcare infrastructure and collaboration with research institutions. These advancements are improving testing capabilities and fostering innovation.

North America held the largest share of the global market in 2023, with 45.6%, due to rising rates of hematological cancers and the swift adoption of advanced testing technologies. The U.S. market is set to grow at a CAGR of 14.1% from 2024 to 2032, supported by advancements in healthcare infrastructure, favorable reimbursement policies, and regulatory endorsements for novel testing methods.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360º synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increase in diagnosis rate of hematological cancers
    • 3.2.1.2 Improved healthcare infrastructure
    • 3.2.1.3 Advancement in diagnostic technologies
    • 3.2.1.4 Increasing incidence of hematologic malignancies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Competition from alternative diagnostic methods
    • 3.2.2.2 High maintenance and operational cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Instrument
  • 5.2.1 Next-generation sequencing (NGS)
  • 5.2.2 Polymerase chain reaction (PCR)
  • 5.2.3 Flow cytometry
  • 5.2.4 Cytogenetics
  • 5.2.5 Immunohistochemistry (IHC)
  • 5.2.6 Other technologies
• 5.3 Kits and reagents
• 5.4 Software and service

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Leukemia
  • 6.2.1 Acute lymphoblastic leukemia (ALL)
  • 6.2.2 Acute myeloid leukemia (AML)
  • 6.2.3 Chronic lymphocytic leukemia (CLL)
  • 6.2.4 Chronic myeloid leukemia (CML)
• 6.3 Lymphoma
  • 6.3.1 Hodgkin lymphoma
  • 6.3.2 Non-Hodgkin lymphoma (NHL)
• 6.4 Other cancer types

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Diagnostic laboratories
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 ARUP Laboratories
• 9.3 Bio-Rad Laboratories Inc.
• 9.4 Danaher Corporation (Integrated DNA Technologies, Inc.)
• 9.5 Entrogen Inc.
• 9.6 F. Hoffmann-La Roche Ltd
• 9.7 Illumina, Inc.
• 9.8 Invivoscribe, Inc.
• 9.9 Invitae Corporation (Archerdx, Inc.)
• 9.10 QIAGEN N.V.
• 9.11 Thermo Fisher Scientific, Inc.
• 9.12 Vela Diagnostics